Falchook, Gerald S <br/><br/>
Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.  [electronic resource] 

 -  Head & neck  Mar 2014 
 - E25-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1097-0347 
<br/><br/><label>Standard No.: </label>10.1002/hed.23429  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Agents--metabolism<br/>Bevacizumab<br/>Drug Therapy, Combination<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Immunohistochemistry<br/>Lapatinib<br/>Male<br/>Middle Aged<br/>Neoplasm, Residual<br/>Quinazolines--administration & dosage<br/>Receptor, ErbB-2--metabolism<br/>Salivary Ducts<br/>Salivary Gland Neoplasms--drug therapy<br/>Trastuzumab<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors